OMIC — Singular Genomics Systems Income Statement
0.000.00%
Last trade - 00:00- $50.26m
- -$53.51m
- $2.91m
Annual income statement for Singular Genomics Systems, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.765 | 2.91 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | -0.024 | -0.558 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.8 | 27.5 | 61.3 | 94.3 | 106 |
| Operating Profit | -12.8 | -27.5 | -61.3 | -93.5 | -103 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12.3 | -27.9 | -98.8 | -90.9 | -94.8 |
| Net Income After Taxes | -12.3 | -27.9 | -98.8 | -90.9 | -94.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12.3 | -27.9 | -98.8 | -90.9 | -94.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.3 | -27.9 | -98.8 | -90.9 | -94.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.33 | -12.1 | -63 | -38.3 | -38.3 |
| Dividends per Share |